Search results for "AIFA"

showing 7 items of 7 documents

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

2020

Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…

Coronavirus COVID-19 Pneumonia SARS-CoV-2 TocilizumabGCA Giant cell arteritispJIA Pediatric juvenile idiopathic arthritislaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineClinical efficacyCPAP Continuous positive airway pressureCOVID-19 Coronavirus disease 2019IDSA Infectious Diseases Society of AmericaRA Rheumatoid arthritisTocilizumabIMV Invasive mechanical ventilationsJIA Juvenile idiopathic arthritisAIFA Agenzia Italiana del FarmacoPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEAntibodies Monoclonal HumanizedNIH U.S. National Institutes of HealthArticleWHO World Health OrganizationSIMIT Italian Society of Infectious and Tropical disease03 medical and health sciencesTocilizumabARDS Acute respiratory distress syndromeAnimalsHumansIn patientIntensive care medicineTocilizumab ; COVID-19 ; Pneumonia ; SARS-CoV-2 ; Coronaviruslcsh:RC705-779business.industryCRS CAR-T cell-induced cytokine release syndromeInterleukin-6SARS-CoV-2NIV Noninvasive mechanical ventilationTNF Tumor necrosis factorCOVID-19Pneumonialcsh:Diseases of the respiratory systemCOVID-19 Drug TreatmentClinical trialCoronavirus030228 respiratory systemchemistrybusinessICTRP International Clinical Trials Registry PlatformPulmonology
researchProduct

Džeknaifa empīriskās ticamības metodes izmantošana ticamības intervālu konstruēšanai laukumam zem ROC līknes

2015

Mūsdienās arvien lielāku popularitāti gūst neparametriskās statistikas metodes. Viena no šādām plaši izmantotajām metodēm ir empīriskās ticamības metode (EL). To kombinējot ar džeknaifa pseido vērtībām, iegūst džeknaifa empīrisko ticamības metodi (JEL). Šī darba mērķis ir pētīt JEL metodes izmantošanas iespējas normalizēto parciālo laukumu zem ROC līknes (AUC) novērtēšanā. Izmantojot šo metodi, tika konstruēti ticamības intervāli gan vienam normalizētajam parciālajam AUC, gan laukumu starpībai. Darba gaitā tika veiktas arī simulācijas, kas parādīja, ka džeknaifa empīriskās ticamības metode strādā ievērojami labāk par normālās aproksimācijas metodi, kā arī tika apskatīts metodes pielietojums…

empīriskās ticamības metodeROC līknedžeknaifa pseido vērtībasnormalizēts parciālais laukums zem ROC līknesMatemātika
researchProduct

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

2016

Aims: The objective of this study was to evaluate the prevalence of the prescription of QT-prolonging drugs at hospital admission and discharge and the risk factors associated with their use in older people (aged 65 years and older). Methods: Data were obtained from the REPOSI (REgistro POliterapie SIMI [Società Italiana di Medicina Interna]) registry, which enrolled 4035 patients in 2008 (n = 1332), 2010 (n = 1380), and 2012 (n = 1323). Multivariable logistic regression was performed to determine the risk factors independently associated with QT-prolonging drug use. QT-prolonging drugs were classified by the risk of Torsades de Pointes (TdP) (definite, possible, or conditional) acc…

MaleTORSADES-DE-POINTES INTERVAL PROLONGATION PATIENT CIPROFLOXACIN COHORT DEATH MULTIMORBIDITY AMIODARONE MORTALITY AIFA.Amiodarone030204 cardiovascular system & hematologyCIPROFLOXACINLogistic regressionAmiodaroneElectrocardiography0302 clinical medicineRisk FactorsTorsades de PointesAtrial Fibrillation80 and overPrevalencePharmacology (medical)030212 general & internal medicineAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalizationmedia_commonAged 80 and overTorsades de PointeAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Pharmacology (medical); Geriatrics and Gerontology; Medicine (all)Medicine (all)DEATHMiddle AgedPatient DischargeHospitalizationLong QT SyndromeCohortHospitalized Older PeopleFemalemedicine.drugHumanDrugmedicine.medical_specialtymedia_common.quotation_subjectMULTIMORBIDITYTorsades de pointesPATIENT03 medical and health sciencesPharmacotherapyInternal medicineINTERVAL PROLONGATIONmedicineHumansTORSADES-DE-POINTESCOHORTMedical prescriptionAIFAAgedbusiness.industryMORTALITYRisk FactorSettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseQT-Prolonging DrugAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Geriatrics and Gerontology; Pharmacology (medical)Physical therapyGeriatrics and Gerontologybusiness
researchProduct

Uso delle eparine a basso peso molecolare in chirurgia generale e d'urgenza

L’Eparina è un mucopolisaccaride estratto da alcuni organi quali il polmone, fegato e mucosa intestinale e si lega alla superficie delle cellule endoteliali. La sua attività biologica richiede la presenza di un cofattore plasmatico ad attività inibitrice proteasica [Antitrombina III], che inibisce i fattori proteasici della coagulazione formando con essi complessi stabili equimolari. In assenza di eparina, tali reazioni sono lente, mentre al contrario sono accelerate di quasi 1000 volte. Le molecole di Eparina sono altamente attive e si legano fortemente all’Antitrombina, determinando alterazioni conformazionali dell’inibitore: tali modifiche espongono il suo sito attivo per una più rapida …

Eparine a basso peso molecolare AIFASettore BIO/14 - Farmacologia
researchProduct

Džekknaifa metodes pielietojums Kaplāna-Meiera integrālim

2020

Cenzētu izdzīvošanas datu vidējā izdzīvošanas ilguma novērtēšanai literatūrā atrodamas vairākas metodes. Darbā aplūkota Džekknaifa metode Kaplāna-Meiera integrālim, Kaplāna-Meiera novērtētājs izdzīvošanas datiem, B.Efrona pieeja vidējā izdzīvošanas ilguma noteikšanai cenzētiem datiem, kā arī apskatīta datorprogrammas RStudio pieejamā pakotne jackknifeKME. Apskatīti dažādu novērtētāju rezultāti vidējam izdzīvošanas ilgumam simulētiem datiem un reālu datu piemēriem.

datu cenzēšanaMatemātikaizdzīvošanas analīzeDžekknaifa metodeKaplāna-Meiera integrālis
researchProduct

Revaluation of the clinical and metabolic behavior of GHD children during GH treatment according to newly proposed note 39 of the Italian Medicines A…

2015

Background The newly proposed note 39 of the Italian Medicines Agency (AIFA) revisited the diagnostic criteria of growth hormone deficiency (GHD) in children and, applying it, a percentage of children previously diagnosed as GHD may have received a wrong diagnosis and a unnecessary treatment, with potential clinical implications. Aim To evaluate the clinical and metabolic behavior of GH-treated children according to the new criteria of GHD diagnosis. Subjects and Methods: We retrospectively analyzed clinical and metabolic data of 310 prepubertal children (220 M, 90 F, age 10.8 ± 2.9 yrs) with short stature admitted to our section of Endocrinology during the years 2005-2014, having at least …

growth hormone AIFA note
researchProduct

Alma Mater: 2014/ Pavasaris

2014

Andra Čudare. Studentu students Rūta Mājeniece -- Studiju prakse - piedzīvo grāmatās rakstīto -- Lauma Abramoviča. Inta Brūna: cilvēks var padarīt ļoti daudz, ja vēlas -- LU Preses centrs. Prezentē jaunās Zobārstniecības mācību klīnikas telpas un programmu -- LU Preses centrs. Latvijas Universitāte Eiropas kultūras kontekstā -- Katrīna Žukova. LU dienesta romāni un mīlas stāsti -- Grācija Tafuni. Nevīžība un precizitāte: vienas medaļas divas puses -- Santa Margēviča. Klase aizraujošām mācībām -- LU Preses centrs. Pasniegtas ikgadējās Latvijas Universitātes Gada balvas -- Kristaps Gustsons. Latvijas Universitātes studente Soču olimpiskajās spēlēs -- Laine Dobulāne. LU Fonda stipendijas – amb…

Rūta MājenieceStudenta kurpēsLU fonda stipendijasErasmus studentu apmaiņas programma - studentiHaifas universitāteLU gada balvaLU absolventi - atmiņasAktuālie notikumi Latvijas UniversitātēProfesore Inta BrūnaLU Zobārstniecības mācību klīnikaLelde PriedulēnaLU Studentu padomeStudiju prakseLU Dabaszinātņu un matemātikas izglītības centrs - mācību klaseLU Rīga-2014Soču olimpiskās spēles
researchProduct